Xi'an Qin Kai Biotech Co., Ltd., established in 2005, specializes in the research, development, production, and sales of active pharmaceutical ingredients(API) and pharmaceutical intermediates. The company currently offers over 100 products across six major categories, with core strengths focused on the full-chain development and manufacturing of vitamin D derivatives, related intermediates, and impurity reference standards. Key products include Eldecalcitol, Calcipotriol, Paricalcitol, Calcitriol, Maxacalcitol, Calcifediol, Doxercalciferol, Alfacalcidol and others. Through years of continuous investment, the company has accumulated substantial technical expertise and established stable industrialization capabilities in the field of vitamin D derivatives.
The company's R&D and production systems have undergone continuous upgrades. In 2018, a 2,200-square-meter R&D and office facility was completed within the Xi'an High-tech Enterprises Accelerator Park, located in Caotang Town, Huyi District, Xi'an City, equipped with core analytical instruments such as GC, HPLC, and preparative liquid chromatographs. The company maintains close collaborations with local universities to share access to large-scale equipment including nuclear magnetic resonance spectrometers and single-crystal X-ray diffractometers. In 2025, an additional 1,700-square-meter R&D and analytical laboratory was put into service within the same park, further consolidating its hardware foundation for technological innovation.To meet growing production demands, the company plans to construct and commission a 1,600-square-meter manufacturing base in Binzhou City, Shaanxi Province, by 2026.
Xi'an Qin Kai Biotech Co., Ltd. is committed to the principle of "Quality First, Customers Superme," providing high-quality products and professional technical services for domestic and overseas clients, and working together to advance the development of a high-standard active pharmaceutical ingredients supply chain.
